Basket | Login | Register

 
 
 
 

P29. Neuronet: Diagnosis, patient engagement and trials

Detailed programme and abstracts

Abstracts will be available soon

P29.1. AMYPAD - Amyloid imaging to prevent Alzheimer’s disease

MOLINUEVO José Luis

BarcelonaBeta Brain Research Center, Barcelona, Spain

Beta-amyloid (β-amyloid) deposition is the considered to be a necessary - albeit not sufficient - step on the path towards development of Alzheimer’s disease (AD). Depiction of brain β-amyloidin vivocan therefore be used to support an early diagnosis of AD and, when recognized in a presymptomatic population, provides an opportunity to consider secondary prevention of AD. Understanding the value of imaging of β-amyloid using positron emission tomography (PET) provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of patients suspected to have AD and their management; 2) understand the natural history of AD in a presymptomatic stage; and 3) select patients for treatment trials aiming at preventing AD by ensuring more homogeneous and appropriate enrolment.

The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) will fulfill those goals through two different studies: The Prognostic and Natural History Study (PNHS) and the (Diagnostic and Patient Management Study (DPMS).

The DPNS will determine in a real-world clinical setting for whom β-amyloid imaging is appropriate, when this is best performed and how the resulting information is influencing diagnostic certainty, patient management and ultimately decision trees and cost-effectiveness of dementia care. This will be performed through a randomized clinical trial including subjective cognitive decline, mild cognitive impairment and dementia patients suspected to be due to AD. The DPNS has already included over 450 patients and is aiming to reach 900.

On the other hand, the Prognostic AMYPAD PNHS will study the natural history of amyloid deposition in liaison with the European Prevention of Alzheimer Dementia (EPAD) study. This study will provide a relevant imaging biomarker dimension complementary to CSF amyloid and will complement the phenotyping and disease modelling efforts in EPAD to improve anti-amyloid treatment monitoring. In addition, the PHNS will include additional non EPAD cohorts which include preclinical and prodromal AD participants. The PHNS is expecting to include 2000 participants with a strong focus on longitudinal imaging of cognitively unimpaired subject with intermediate amyloid levels. 

P29.2. EPAD - European prevention of Alzheimer’s dementia consortium

RITCHIE Craig

United Kingdom

P29.3. MOPEAD - Models of patient engagement for Alzheimer’s disease

BOADA Mercè

Spain

P29.4. RADAR-AD - Remote assessment of disease and relapse – Alzheimer’s disease

AARSLAND Dag, OWENS Andrew

King’s College London, London, United Kingdom

Alzheimer’s disease (AD) leads to impaired functioning, i.e. the ability to perform activities of daily living. Until recently, measuring the patient’s ability to function has relied on direct clinical observation or caregiver recall at discrete intervals. This limits the reliability and sensitivity to change, which is especially relevant, as functional impairment is required for differentiation between dementia and mild cognitive impairment and is a key outcome for clinical trials in AD. In addition, recent studies have found that subtle functional impairment occurs also during pre-dementia AD. The enormous advances in health-care devices, including portal technologies and wireless communications, allow measuring function in AD patients’ everyday environment using Remote Measurement Technologies (RMTs), providing the opportunity to capture detailed data over numerous time points.

The goal of the Innovative Medicines Initiative (IMI) Remote Assessment of Disease and Relapse (RADAR)-AD project is the development and validation of technology-enabled, quantitative and sensitive measures of functional domains in people with early stage AD. To achieve this, we will, in close collaboration with patient organizations and regulators, select, and if needed, modify, the most relevant available devices that can sensitively measure early and clinically meaningful functional decline in people with AD. We will validate the selected devices in a cross-sectional multicenter observational clinical study of 220 individuals across the AD spectrum.

The RADAR-AD’s tailored combination of devices and smartphone applications, which began early 2019, will act as a powerful new tool in personalised medicine. During the first 6 months we have prioritised functional domains that are declining early in AD and being ranked as important by Alzheimer’s Europe’s Patient Advisory Group. We have selected the most relevant RMTs, and developed the trial protocol, including a substudy that involves technologies being installed in the subjects’ home. RADAR-AD finishes in 2022.

 This session is organised by Neuronet.

 

 
 

Last Updated: Tuesday 13 August 2019

 

 
  • Acknowledgements

    The 29th AE Conference in The Hague received funding under an operating grant from the European Union’s Health Programme (2014-2020). Alzheimer Europe and Alzheimer Nederlands gratefully acknowledge the support of all conference sponsors.
  • European Union
  • Roche
 
 

Options